Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer

Koji Inaba1,*, Keisuke Tsuchida1,2, Tairo Kashihara1, Rei Umezawa1,3, Kana Takahashi1, Kae Okuma1, Naoya Murakami1, Yoshinori Ito1,4, Hiroshi Igaki1, Minako Sumi1,5, Yuko Nakayama1, Yasuo Shinoda6, Tomohiko Hara6, Yoshiyuki Matsui6, Motokiyo Komiyama6, Hiroyuki Fujimoto6 and Jun Itami1

1Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
2Department of Radiation Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan
3Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryou-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan
4Department of Radiation Oncology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
5Department of Radiation Oncology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan
6Department of Urology, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo 104-0045, Japan

*Corresponding author. Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Tel: +81-3-3542-2511; Fax: +81-3-3545-3567; Email: koinaba@ncc.go.jp
(Received 3 March 2020; revised 12 June 2020; editorial decision 17 June 2020)

ABSTRACT

Although systemic therapy is the standard treatment for metastatic prostate cancer, a randomized controlled trial showed radiotherapy to the prostate improved overall survival of metastatic prostate cancer patients with the low metastatic burden. Additionally, a randomized phase II trial showed that metastasis-directed therapy for oligo-recurrent prostate cancer improved androgen-deprivation therapy (ADT)-free survival. Therefore, administering radiotherapy to both prostate and metastatic regions might result in better outcomes. Thus, we report the treatment results of radiotherapy to both prostate and metastatic regions. Our institutional database was searched for patients who received radiotherapy to the prostate and metastatic regions. We summarized patient characteristics and treatment efficacy and performed statistical analysis to find possible prognostic factors. A total of 35 patients were included in this study. The median age was 66 years, and the median initial prostate-specific antigen (PSA) level was 32 ng/ml. The Gleason score was 7 in 10 patients, 8 in 13 patients, and 9 in 12 patients. The median radiotherapy dose was 72 Gy to the prostate and 50 Gy to the metastatic bone region. The 8-year overall survival, cause-specific survival, progression-free survival, and freedom from biochemical failure rate were 81, 85, 53, and 57%. Among the 35 patients, 12 were disease-free even after ADT was discontinued. In selected patients with metastatic prostate cancer, ADT and radiotherapy to the prostate and metastatic sites were effective. Patients with good response to ADT may benefit from radiotherapy to both prostate and metastatic regions.

Keywords: prostate cancer; metastatic prostate cancer; radiotherapy for both prostate and bone metastasis; radiotherapy for bone metastasis

INTRODUCTION

The standard of care for metastatic prostate cancer is mainly systemic treatment [1–7]; nevertheless, prostate cancer develops castration resistance over several years and median survival was reported to be several years [1,3–5,8–10]. A randomized controlled trial showed that radiotherapy to the prostate improved the overall survival of the
prespecified low metastatic burden subgroup in the metastatic prostate cancer [11]. Additionally, there is a study that showed metastasis-directed therapy improved androgen-deprivation therapy (ADT)-free survival in patients with oligo-recurrent prostate cancer when compared with surveillance [12]. Therefore, radiotherapy to not only the prostate but also the metastatic regions has the potential to improve outcome [13]. In our institution, definitive radiotherapy is sometimes administered to the prostate including the metastatic bone region when bone metastasis was observed near the pelvis or when the number of bone metastasis was small. The rationale is that some patients with metastatic prostate cancer show the symptoms associated with local invasion of prostate cancer such as urinary obstruction or hematuria and symptoms related to bone metastasis such as pain or fracture as the disease progresses. Moreover, we administered whole pelvic radiotherapy for locally advanced prostate cancer [14]. Therefore, administering radiotherapy to the metastatic sites that were located within and near the pelvis did not seem to increase the toxicity. The current study was conducted to analyze the efficacy of radiotherapy on prostate cancer with bone metastasis by irradiating both the prostate and the metastatic regions.

**MATERIALS AND METHODS**

Our institutional database was searched for patients who underwent radiotherapy to both the prostate and metastatic regions. We summarized the patient and treatment characteristics, treatment efficacy, and adverse effects related to radiotherapy. The metastatic burden was categorized according to the definition used in the CHAARTED trial [3].

The freedom from biochemical failure (FFBF) rate, progression-free survival (PFS) rate, overall survival (OS) rate, and cause-specific survival (CSS) rate were calculated with the Kaplan–Meier method from the start of treatment. Biochemical failure was defined as the nadir prostate-specific antigen (PSA) level plus 2 ng/ml using the Phoenix definition [15]. A PFS event was defined as the observation of any clinical failure (local, nodal, or distant recurrence) or death. Univariate analysis was performed to determine the possible prognostic factors for FFFB, PFS, OS, and CSS by using the log-rank test. The analyzed possible factors were age < 66 years vs ≥66 years, PSA level < 80 ng/ml vs ≥80 ng/ml, Gleason score (GS) ≤8 vs ≥9, diagnosis before 2005 vs after 2005, PSA level before radiotherapy < 1 ng/ml vs ≥1 ng/ml, and the duration of ADT, neoadjuvant ADT, and adjuvant ADT. A P-value < 0.05 was considered statistically significant. Morbidities were classified according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0). Acute adverse events were defined as any adverse events that occurred within 3 months from the start of radiotherapy. Late adverse events were defined as any adverse events that occurred after 3 months from the start of radiotherapy. Statistical analyses were performed with JMP® 14 (SAS Institute Inc., Cary, NC, USA). Our Institutional Review Board (National Cancer Center, Tokyo, Japan) approved this study. All treatments were performed after obtaining patient consent.

| Table 1. Patients characteristics |
|----------------------------------|
| Characteristics                  |
| Age, years                       | Median 66 (44–76) |
| PS (0–1)                         | 35 |
| Year of diagnosis                |
| 1995–2001                         | 4 |
| 2002–2005                         | 14 |
| 2006–2009                         | 5 |
| 2010–2014                         | 7 |
| 2015–2017                         | 5 |
| PSA, ng/ml                       | Median 32 (5–11750) |
| GS                               |
| 7                                | 10 |
| 8                                | 13 |
| 9                                | 12 |
| T stage                          |
| T1                               | 3 |
| T2                               | 5 |
| T3                               | 18 |
| T4                               | 8 |
| Tx                               | 1 |
| N stage                          |
| N0                               | 24 |
| N1                               | 11 |
| The location of bone metastasis  |
| Pelvic bone                      | 27 |
| Pelvic bone + lumbar vertebra    | 1 |
| Pelvic bone + lumbar and thoracic and cervical vertebra | 1 |
| Pelvic bone + lumbar vertebra and rib | 1 |
| Pelvic bone + rib + cranial bone | 1 |
| Femoral bone                     | 1 |
| Lumbar vertebra                  | 2 |
| Lumbar and thoracic vertebra and rib | 1 |
| PSA value before radiotherapy, ng/ml |
| < 1                              | 25 |
| 1 >=                             | 10 |
| Follow up period, months         | Median 94 (12–256) |

**RESULTS**

A total of 35 patients were treated with radiotherapy by irradiating the prostate and the metastatic bone regions in our institution between 1995 and 2017. The patient characteristics are summarized in Table 1. The median age was 66 years (range: 44–76 years), and the median initial PSA level was 32 ng/ml (range: 5–11 750 ng/ml). The GS was 7 in 10 patients, 8 in 13 patients, and 9 in 12 patients. Bone metastasis was located in the pelvic bone in 27 patients and outside the pelvis in 8 patients. Two patients were classified into the high metastatic burden group, while the remaining 33 patients were classified into the low metastatic burden group. Twenty five patients had PSA value before radiotherapy < 1 ng/ml and ten patients ≥1 ng/ml.

The treatment characteristics are shown in Table 2. Radiotherapy to the prostate was performed with conventional fractionation but only 1 patient with high-dose-rate (HDR) brachytherapy. Regarding bone
Radiotherapy for metastatic prostate cancer

Table 2. Treatment characteristics

| Characteristics                  | N  |
|----------------------------------|----|
| RT method                        |    |
| 2D                               | 11 |
| 2D + 3DCRT                       | 8  |
| 3DCRT                            | 2  |
| IMRT                             | 10 |
| IMRT + 3DCRT                     | 3  |
| IMRT + HDR brachytherapy         | 1  |
| RT dose                          |    |
| Prostate                         |    |
| 15 Gy/1 fraction (HDR brachytherapy) + 46 Gy | 1 |
| 80 Gy                            | 2  |
| 78 Gy                            | 8  |
| 72 Gy                            | 12 |
| 66 Gy                            | 5  |
| 64 Gy                            | 1  |
| 50 Gy                            | 6  |
| Pelvic lymph node region         |    |
| For metastatic lymph node        |    |
| 65 Gy                            | 1  |
| 60 Gy                            | 6  |
| 54 Gy                            | 2  |
| 50 Gy                            | 1  |
| 46 Gy                            | 1  |
| For prophylactic                 |    |
| 50 Gy                            | 6  |
| 46 Gy                            | 23 |
| 40 Gy                            | 4  |
| Metastatic bone                  |    |
| 72 Gy                            | 1  |
| 66 Gy                            | 1  |
| 65 Gy                            | 1  |
| 63 Gy                            | 1  |
| 60 Gy                            | 5  |
| 56 Gy                            | 1  |
| 55.2 Gy                          | 1  |
| 54 Gy                            | 1  |
| 50 Gy                            | 7  |
| 46 Gy                            | 10 |
| 40 Gy                            | 4  |
| 30 Gy                            | 2  |
| Neo adjuvant ADT                  | 34 patients |
| Median 9 months (2–44 months)    |    |
| Adjuvant ADT                     | 25 patients |
| Median 17 months (2–94 months)   |    |

2D = 2 dimensional.
3DCRT = 3 dimensional conformal radiotherapy.
IMRT = Intensity-modulated radiotherapy.
HDR = High-dose-rate.
ADT = Androgen-deprivation therapy.

metastasis, intensity-modulated radiotherapy (IMRT) was performed in 12 patients and 2D or 3D radiotherapy planning in 23 patients with various dose fractionation.

The median radiotherapy dose to the prostate was 72 Gy (range: 50–80 Gy, 1 patient was treated with HDR brachytherapy of 15 Gy / 1 fraction and IMRT) and that to the metastatic bone region was 50 Gy (range: 30–72 Gy). In 33 patients, prophylactic irradiation to the pelvic lymph node regions was performed with a median dose of 46 Gy (range: 40–50 Gy). ADT was administered to all 35 patients. Neoadjuvant ADT was administered to 34 patients with a median length of 9 months (range: 2–44 months). Adjuvant ADT was administered to 25 patients with a median length of 17 months (range: 2–94 months). The median follow-up duration was 94 months (range: 12–256 months). The FFBF, PFS, OS, and CSS rates were 68, 88, 94, and 94% at 3 years and 57, 53, 81, and 85% at 8 years (Fig. 1). Of the 35 included patients, 12 were free from disease after discontinuing ADT, and the median length of being disease-free after discontinuing ADT was 102 months (range: 16–162 months). Univariate analyses showed that a PSA level before radiotherapy < 1 ng/ml was a good prognostic factor for FFBF, PFS, OS, and CSS (Fig. 2, Table 3, and Table 4).

Adverse events related to radiotherapy are summarized in Table 5. A grade 3 acute adverse event was observed in 3 patients. A grade 3 late adverse event was observed in 1 patient.

DISCUSSION

The results of the current study proved that some patients with metastatic prostate cancer could be long-time survivors after receiving radiotherapy to both the prostate and metastatic regions, indicating that radiotherapy has the potential to improve the FFBF, PFS, OS, and CSS rates of patients with prostate cancer with bone metastasis. A PSA level before radiotherapy < 1 ng/ml was a good prognostic factor for FFBF, PFS, OS, and CSS.

Several retrospective and prospective studies have evaluated the efficacy of local therapy for prostate cancer which is considered to be a systemic disease [11, 16–18]. For example, the STAMPEDE trial showed that local radiotherapy to the prostate improved the overall survival in patients with a low metastatic burden [11]. Moreover, there is a study that reported metastasis-directed therapy for oligo-recurrent prostate cancer improved ADT-free survival when compared with surveillance [12]. In our institution, the use of whole pelvic irradiation for locally advanced prostate cancer was previously evaluated [14]. It has often been used for locally advanced prostate cancer. Hence, 33 of 35 patients (94%) in this study received elective pelvic lymph node irradiation. This treatment was performed after adequate discussion of treatment with urologists and radiation oncologists. The reasons for administering this treatment were mainly the good response to ADT (as determined by good reduction in PSA levels, good radiological results, and no new lesions after ADT), the small metastatic volume, and the easy inclusion of the target regions in the radiation field (meaning that whole pelvic irradiation and additional small radiation fields were sufficient to cover the lesions).

In the STAMPEDE trial, the patients who were allocated radiotherapy had a 3-year failure-free survival rate of 50%, PFS rate of 63%, OS rate of 81%, and CSS rate of 86% in the low metastatic burden group [11]. In the current study, the 3-year FFBF rate was 68%, PFS rate was 88%, OS rate was 94%, and CSS rate was 94%. Furthermore, 12 of 35 patients were disease-free after discontinuing ADT, which has a strong impact on the clinical practice for prostate cancer with bone metastasis. Therefore, the treatment strategy of radiotherapy to both the prostate and metastatic regions seems a promising method, and this study could be the basis for phase II and III well-designed prospective studies on the use of radiotherapy to the prostate and metastatic regions in patients with metastatic prostate cancer.
Fig. 1. Freedom from biochemical failure (FFBF), progression-free survival (PFS), overall survival (OS), and cause-specific survival (CSS) for all patients.

Table 3. Statistical analysis of freedom from biochemical failure (FFBF) and progression-free survival (PFS)

| Factors                                      | FFBF Univariate analysis | P value (log-rank test) | FFS Univariate analysis | P value (log-rank test) |
|----------------------------------------------|--------------------------|-------------------------|-------------------------|-------------------------|
| GS $\geq 9$ vs $\leq 8$                     | (12/23)                  | 3 year (8 year) FFBF    | 0.56                    | 3 year (8 year) PFS     | 0.44                    |
| PSA $\geq 80$ ng/ml vs $< 80$ ng/ml          | (12/23)                  | 49% (49%) vs 77% (61%)  | 0.0062                  | 81% (52%) vs 91% (53%)  | 0.23                    |
| Diagnosis year before 2005 vs diagnosis year after 2006 | (18/17)                  | 67% (50%) vs 67% (67%)  | 0.28                    | 89% (50%) vs 86% (64%)  | 0.69                    |
| Age $\geq 66$ years vs age $< 66$ years      | (21/14)                  | 65% (46%) vs 71% (71%)  | 0.54                    | 90% (46%) vs 86% (59%)  | 0.73                    |
| Length of ADT $\geq 1$ year vs $< 1$ year   | (29/6)                   | 68% (54%) vs 67% (67%)  | 0.57                    | 86% (51%) vs 100% (50%) | 0.63                    |
| Length of neoadjuvant ADT $\geq 6$ months vs $< 6$ months | (25/9)                   | 69% (54%) vs 65% (65%)  | 0.87                    | 88% (54%) vs 100% (50%) | 0.99                    |
| Length of adjuvant ADT $\geq 6$ months vs $< 6$ months | (19/6)                   | 70% (56%) vs 80% (53%)  | 0.92                    | 83% (47%) vs 83% (42%)  | 0.99                    |
| PSA value before radiotherapy $\geq 1$ ng/ml vs $< 1$ ng/ml | (10/25)                  | 54% (20%) vs 73% (68%)  | 0.0076                  | 70% (0%) vs 95% (68%)   | < 0.0001                |

ADT: Androgen-deprivation therapy
GS: Gleason score

Our study has several limitations in addition to the retrospective nature and small sample size. The main limitation is selection bias. This treatment was performed in a limited population. Many patients in this study had small bone metastasis located within and near the pelvis, and they showed a good response to ADT; such patients account for a small number of patients with metastatic prostate cancer. Therefore,
Radiotherapy for metastatic prostate cancer

Fig. 2. Freedom from biochemical failure (FFBF), progression-free survival (PFS), overall survival (OS), and cause-specific survival (CSS) for the PSA level before radiotherapy $\geq 1$ ng/ml vs $< 1$ ng/ml.

Table 4. Statistical analysis of overall survival (OS) and cause-specific survival (CSS)

| Factors                                     | N   | OS Univariate analysis | P value (log-rank test) | CSS Univariate analysis | P value (log-rank test) |
|---------------------------------------------|-----|------------------------|-------------------------|-------------------------|-------------------------|
| GS $\geq 9$ vs $\leq 8$                     | (12/23) | 90% (68%) vs 96% (85%) | 0.46                    | 90% (90%) vs 96% (85%)  | 0.77                    |
| PSA $\geq 80$ ng/ml vs $< 80$ ng/ml         | (24/25) | 70% (100%) vs 94% (84%) | 0.14                    | 95% (87%) vs 94% (84%)  | 0.93                    |
| Diagnosis year before 2005 vs diagnosis year after 2006 | (18/17) | 94% (78%) vs 94% (94%) | 0.51                    | 94% (83%) vs 94% (94%)  | 0.61                    |
| Age $\geq 66$ years vs age $< 66$ years     | (21/14) | 95% (87%) vs 93% (73%) | 0.07                    | 95% (87%) vs 93% (84%)  | 0.93                    |
| Length of ADT $\geq 1$ year vs ADT $< 1$ year | (29/6)  | 93% (76%) vs 100% (100%) | 0.50                    | 95% (81%) vs 100% (100%) | 0.21                    |
| Length of neoadjuvant ADT $\geq 6$ months vs $< 6$ months | (25/9)  | 92% (79%) vs 100% (80%) | 0.72                    | 92% (86%) vs 100% (80%) | 0.88                    |
| Length of adjuvant ADT $\geq 6$ months vs $< 6$ months | (19/6)  | 94% (72%) vs 83% (83%) | 0.62                    | 94% (72%) vs 83% (83%)  | 0.91                    |
| PSA value before radiotherapy $\geq 1$ ng/ml vs $< 1$ ng/ml | (10/25) | 80% (40%) vs 100% (94%) | 0.01                    | 80% (40%) vs 100% (100%) | 0.0005                  |

OS: Overall survival
CSS: Cause-specific survival
GS: Gleason score
ADT: Androgen-deprivation therapy

Further research is needed on how these results could be applied to the treatment of metastatic prostate cancer. However, the important finding obtained in this study is that some patients with metastasis could obtain a good outcome after definitive radiotherapy to both the prostate and metastatic regions. In addition, another limitation is the low dose of 30 or 40 Gy to the metastatic bones in some patients. It does not seem to be enough dose to control the tumor. These patients were treated with 2D or 3D radiotherapy planning which was difficult to prescribe a high dose. Further research regarding dose to metastatic sites is needed.

In conclusion, we reported good results of ADT and radiotherapy to both the prostate and metastatic regions in patients with prostate cancer with a few bone metastasis. In selected prostate cancer patients with bone metastasis, ADT and radiotherapy to the prostate and the
metastatic bone regions could be a promising treatment. Patients with a good response to ADT may benefit from radiotherapy to both the prostate and metastatic regions.

CONFLICT OF INTEREST

Dr. Inaba reports grants from Elekta K.K., outside the submitted work. Dr. Igaki reports grants from HekaBio and personal fees from ITOCHU, outside the submitted work. Dr. Nakayama reports personal fees from AstraZeneca, outside the submitted work. Dr. Itami reports personal fees and non-financial support from Kay J, personal fees from Alpha Tau, personal fees from HekaBio, grants from Elekta, and grants from ITOCHU, outside the submitted work. The other authors have no conflicts of interest to declare.

REFERENCES

1. Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737–46.
2. Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone plus enzalutamide in metastatic, castration-resistant prostate cancer: long-term results of the phase III E3805 CHAARTED trial. J Clin Oncol 2018;36:1080–87.
3. Clarke NW, Ali A, Ingleby FC et al. Addition of docetaxel to hormonal therapy in low- and high-risk metastatic hormone-sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 2019;30:1992–2003.
4. Clarke NW, Ali A, Ingleby FC et al. Addition of docetaxel to hormonal therapy in low- and high-risk metastatic hormone-sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 2019;30:1992–2003.
5. Feyerabend S, Saad F, Perualila NJ et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncol 2019;14:681–88.
6. Sathianathan NJ, Koschel S, Thangasamy IA et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol 2020;77:365–72.
7. Marchioni M, Di Nicola M, Primiceri G et al. New antiandrogen compounds compared to docetaxel for metastatic hormone-sensitive prostate cancer: results from a network meta-analysis. J Urol 2020;203:751–59.
8. Halwani AS, Rasmussen KM, Patil V et al. Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urol Oncol 2020;38:1.e1–1.e10.
9. Westerberg M, Franck Lissbrant I, Damber JE et al. Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study. Acta Oncol 2020;59:106–11.
10. Lin TT, Chen YH, Wu YP et al. Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients. J Cancer 2019;10:5608–13.
11. Parker CC, James ND, Brawley CD et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392:2353–66.
12. Ost P, Reynders D, Decaestecker K et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018;36:446–53.
13. Tsumura H, Ishiyama H, Tabata KI et al. Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: a retrospective cohort study. Prostate 2019;79:506–14.
14. Sun M, Ikeda H, Tokuyue K et al. The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostate carcinoma. Int J Radiat Oncol Biol Phys 2020;1080–87.
15. Roach M 3rd, Hanks G, Thomas H Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74.
16. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65:1058–66.
17. Engel J, Bastian PJ, Baur H et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010;57:754–61.
18. Knipper S, Beyer B, Mandel P et al. Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H. World J Urol 2020;38:1459–64.